Healing peptides and tissue repair
When you strain a tendon or overwork a muscle, your body runs a repair sequence: inflammation, new blood vessels, rebuilt tissue. So-called healing peptides like BPC-157 and TB-500 are studied for how they interact with that sequence.
Most of the research so far is preclinical — worth understanding before forming expectations — and these articles are honest about that line. They cover the mechanisms, the evidence, and the practical questions people ask, with every compound available only by prescription after a provider review.
43 articles on this topic
-

BPC-157 and Alcohol: Can You Drink Safely?
No published human study has tested the combination. The alcohol claims come from experiments in mice and rats, which cannot establish a safe drinking amount or a hangover remedy.
-

Gray Market Peptides: What Johns Hopkins Found
Johns Hopkins says the market for unverified peptide vials is growing much faster than the human evidence. The useful question is what a prescription and a pharmacy change.
-

BPC-157 Myths: 10 Claims Checked
Ten familiar claims about BPC-157, graded against the studies: what comes from rats, what has been observed in people, and what remains unknown.
-

BPC-157 Human Studies: What the Evidence Shows
Human evidence exists, but it is much smaller than online summaries make it sound: a few short, uncontrolled reports cannot establish that BPC-157 works or is safe long term.
-

Who Discovered BPC-157? Predrag Sikirić
Predrag Sikirić's group at the University of Zagreb described the parent gastric peptide in 1992 and the 15-amino-acid fragment BPC-157 in 1993. The history is much clearer than the human evidence.
-

KLOW Peptide Before and After: An Honest Timeline
There is no clinical before-and-after timeline for KLOW because no published study has tested the finished blend. Here is what component studies measured over three days to 12 weeks—and why those clocks are not a promise.
-

TB-500 10 mg: What the Vial Size Really Means
A 10 mg mark states the total peptide mass the vial is meant to contain. It is not a per-injection dose, a concentration, or proof that an unverified vial contains what its label claims.
-

Does Tesamorelin Build Muscle? What Trials Show
Tesamorelin raised lean mass modestly in trials of adults with HIV-related lipodystrophy, but that is not proof of bigger or stronger muscles. It has not been shown to build muscle in healthy lifters.
-

Oral TB-500: Why Capsules Lack Human Evidence
There is no human evidence that a TB-500 capsule delivers intact peptide into the bloodstream. The published TB-500 and thymosin beta-4 work used injected or topical routes, so a capsule label cannot prove absorption or an effect.
-

Where to Inject KLOW Peptide: Abdomen or Thigh?
KLOW is given into the fatty layer beneath the skin, usually in an abdomen or thigh area named in the pharmacy directions. The exact boundaries and rotation plan come from the prescription, not from an online diagram.
-

There Is No Best BPC-157 Brand. Ask This Instead.
No company holds an approval to make BPC-157, so the “brands” ranked online are websites, not manufacturers. What's worth comparing is the pharmacy and the prescription behind the vial.
-

BPC-157 WADA Status: Prohibited All Year Round
If you're tested in your sport, the answer is short. BPC-157 is prohibited all year round, a prescription doesn't change that, and the one exemption that could is unlikely to be granted, by USADA's own account.
-

BPC-157 Dosage by Body Weight: No Human Formula
There is no validated weight-based BPC-157 dose for people. The micrograms-per-kilogram numbers online were lifted from rat experiments, not human dose-finding trials.
-

TB-500 Half-Life: The Honest Answer Is Unknown
There is no reliable human half-life for the TB-500 fragment. The familiar one-to-two-hour estimate comes from the 44-amino-acid recombinant study molecule NL005, tested by a different route.
-

Peptide Research 2026: What Three Reviews Found
Three review papers landed within a few weeks of each other this summer. They agree the animal work is real, the human evidence is thin, and that gap is the thing worth understanding.
-

503A Bulks List: What It Means
The 503A bulks list is a narrow ingredient pathway for patient-specific compounding. Here is how it differs from FDA categories, drug review and the separate 503B list.
-

Is BPC-157 FDA Approved? No—The Vote Was Advisory
BPC-157 is not FDA-approved, and no approved BPC-157 product exists anywhere. The July 2026 vote was advice on compounding, not drug approval.
-

Paradigm Peptides: A Lab Certificate Is Not Proof
The Paradigm Peptides sentencing exposed a simple weakness in buying medicine from an unlicensed website: a polished lab certificate can be fake. The safer difference is an accountable chain—a prescriber, a named pharmacy and records regulators can inspect.
-

KLOW Peptide Stack: Four Peptides in One Vial
A “stack” just means taking more than one peptide at a time. KLOW is one that comes already mixed — four peptides in a single prescribed vial, so there is nothing for you to assemble.
-

The FDA Peptide Decision Hasn't Been Made Yet
An FDA advisory panel voted on seven peptides in July. Weeks on, nothing has been published — and that gap is the whole story.
Page 1 of 3 · 43 articles